Lung cancer is one of the most common cause of death worldwide, while non-small cell lung cancer accounts for 85% of all lung cancer cases. Traditionally, the standard of care was platinum- based chemotherapy. However, with the discovery of a wide variety of driver mutations by molecular diagnostic methods, there has been an explosion of new drugs being approved yearly.The main aim of this review is to discuss the available pharmacotherapy for non-small cell lung cancer according to the stage of the disease and molecular status. Also to give a short review about the background knowledge of non-small cell lung cancer, regarding its histological classification, epidemiology, symptomology, diagnostic methods and treatment options.